Advancing the Frontier of Translational Proteomic Insights
Transcript featuring Gary Patti (Panome Bio) and Dipender Gill (Sequoia Genetics) DIPENDER So Gary, great to get a chance to talk again. I know we’ve had numerous really stimulating conversations about proteomics, genetics, the intersection of science, and how...
Surface Proteomics for Smarter Drug Target Discovery
Drug development is expensive, slow, and highly unpredictable. Despite major advances in genomics and precision medicine, nearly 90% of drug candidates still fail (Doi: 10.1016/j.apsb.2022.02.002) during clinical development, often because the selected target was not...
Untargeted Metabolomics Reimagined: Meet MassID™
What if untargeted metabolomics delivered on its promise? For years, untargeted metabolomics has been one of the most compelling approaches in biology: measure broadly, capture molecular diversity and improve biological interpretation and understanding. In practice,...